PIONEER-HF was a multicenter, randomized, double-blind, double dummy, parallel group, active-controlled 8-week study to evaluate the effect of sacubitril and valsartan (LCZ696) versus enalapril on changes in NT-proBNP and safety and tolerability of in-hospital initiation of LCZ696 compared to enalapril in HFrEF patients who have been stabilized following hospitalization for acute decompensated heart failure (ADHF).

Angiotensin–Neprilysin Inhibition in Acute Decompensated Heart Failure


Safety and Efficacy of Sacubitril/Valsartan by Dose Level in Patients Hospitalized with Acute Heart Failure (Morrow ESC 2019)
PIONEER High-risk Subgroups (Berg AHA 2019)


Angiotensin-Neprilysin Inhibition in Black Americans: Data From the PIONEER-HF Trial

Angiotensin Receptor-Neprilysin Inhibition Based on History of Heart Failure and Use of Renin-Angiotensin System Antagonists

Efficacy and Safety of Sacubitril/Valsartan by Dose Level Achieved in the PIONEER-HF Trial

Initiation of Angiotensin-Neprilysin Inhibition After Acute Decompensated Heart Failure: Secondary Analysis of the Open-label Extension of the PIONEER-HF Trial

The Association Between Congestion and Outcomes for Patients Treated With Sacubitril-Valsartan Compared to Enalapril in the PIONEER-HF Trial

Efficacy and Safety of Sacubitril/Valsartan in Acute Decompensated Heart Failure in High-Risk Patients in the PIONEER-HF Trial

Cardiovascular biomarkers in patients with acute decompensated heart failure randomized to sacubitril-valsartan or enalapril in the PIONEER-HF trial

Clinical Outcomes in Patients With Acute Decompensated Heart Failure Randomly Assigned to Sacubitril/Valsartan or Enalapril in the PIONEER-HF Trial

Rationale and design of the comParIson Of sacubitril/valsartaN versus Enalapril on Effect on nt-pRo-bnp in patients stabilized from an acute Heart Failure episode (PIONEER-HF) trial

%d bloggers like this:
search previous next tag category expand menu location phone mail time cart zoom edit close